All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Lorbriqua 25mg Tablet
Prescription Required
Salt Composition : Lorlatinib
Manufacturer : PFIZER LTD
Origin of Medicine : United States of America
30 Tablet(s) In A Bottle
PAP Information : Buy 1, get 1 Free. Contact us for latest updates.
Program Overview: PFIZER LTD, is dedicated to helping patients in need of Lorbriqua 25mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 bottle of Lorbriqua 25mg tablet, and you will receive 1 additional bottle of Lorbriqua 25mg tablets. Therefore, if eligible, you will have to pay only Rs. 82,416 for two bottles, which is Rs. 41,208 per bottle.
With MrMed's MRP discount of Rs. 19,584 per bottle and Pfizer’s PAP program, the overall savings is over 1.2 lakh per purchase.
Eligibility Criteria: To qualify for the Lorbriqua Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Lorlatinib 25mg tablet from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Pfizer can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: PFIZER LTD, is dedicated to helping patients in need of Lorbriqua 25mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 bottle of Lorbriqua 25mg tablet, and you will receive 1 additional bottle of Lorbriqua 25mg tablets. Therefore, if eligible, you will have to pay only Rs. 82,416 for two bottles, which is Rs. 41,208 per bottle.
With MrMed's MRP discount of Rs. 19,584 per bottle and Pfizer’s PAP program, the overall savings is over 1.2 lakh per purchase.
Eligibility Criteria: To qualify for the Lorbriqua Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Lorlatinib 25mg tablet from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Pfizer can avail of it without having to purchase the medication from MrMed.
Introduction to Lorbriqua 25mg Tablet
Lorbriqua 25mg tablet is a drug belonging to the class of tyrosine kinase inhibitors, containing the active ingredient Lorlatinib. It is used to treat metastatic non-small cell lung cancer (NSCLC). This is the most common type of lung cancer. Metastatic non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread to other parts of the body, such as the bones, liver, brain, or other organs.
During the treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause liver damage. Also, it may cause decreased fertility in males and this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
Inform the doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Report to your doctor if you experience any hypersensitive reactions like itchy skin or rashes while taking this medicine. It is advised to avoid drinking grapefruit juice while taking this drug, as it may increase the level of the drug in the blood and cause side effects. This tablet contains lactose as an inactive ingredient in which the body is unable to digest lactose, a sugar found in milk and dairy products. It can cause symptoms such as bloating, and abdominal pain. If you have lactose intolerance, inform your doctor before starting this therapy.
Uses of Lorbriqua 25mg Tablet
- Metastatic non-small cell lung cancer (NSCLC)
Therapeutic Effects of Lorbriqua 25mg Tablet
It works by inhibiting the tyrosine kinases, thus preventing the activation of downstream signalling pathways that are involved in cell proliferation, survival, and differentiation. This leads to the inhibition of cancer cell growth and survival.
Interaction of Lorbriqua 25mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lorbriqua 25mg tablet and reduce effectiveness by causing undesirable side effects.
More Information about Lorbriqua 25mg Tablet
- Store Lorbriqua 25mg tablet in the original package at a controlled room temperature (20°C to 25°C).
- Keep it out of reach from children.
How to consume Lorbriqua 25mg Tablet
Your doctor will decide the dose and duration of Lorbriqua 25mg tablet based on the disease condition and other factors. Take the tablet at the same time every day, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
Safety Advices for Lorbriqua 25mg Tablet
Pregnancy
Lorbriqua 25mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Breast Feeding
It is not known if Lorbriqua 25mg tablets pass into your breast milk or if it will affect your baby. Please consult your doctor before breastfeeding.
Lungs
Inform your doctor if you have any lung problems before taking Lorbriqua 25mg tablet. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Inform your doctor if you have any liver problems before taking Lorbriqua 25mg tablet. Regular monitoring of liver function tests is recommended.
Alcohol
Consuming alcohol may affect the effectiveness of Lorbriqua 25mg tablet. Stop consuming alcohol if you are taking this medicine.
Driving
It is unsafe to drive vehicles or operate heavy machinery after taking Lorbriqua 25mg tablets, it may cause dizziness and impair your concentration.
Side Effects of Lorbriqua 25mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
- Cough, chest pain, or worsening of breathing problems
- Feeling tired, faint, or losing consciousness
- Yellowing of the skin and eyes, vomiting, abdominal pain
- Confusion, memory loss, mood swings, difficulty speaking, seeing, or hearing things that are not real
Common
- Increase in cholesterol levels
- Swelling in hand or legs
- Double vision difficulty seeing
- Pain, numbness, or unusual sensations (burning or pin and needles) in arms and legs, difficulty walking
- Diarrhoea, constipation
- Headache
- Weight gain
- Joint pain, muscle pain
- Rash
- Anaemia
Word of Advice
Lorbriqua 25mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment. Discuss effective nonhormonal contraceptive methods with your healthcare provider and use them during this treatment and continue for at least six months after the last dose. It is not known if this drug passes into breast milk. Hence, it is not recommended to breastfeed during this treatment. This medicine may increase your blood sugar levels. Your healthcare provider should do blood tests to check your blood sugar levels before starting and during treatment with this drug. It is important to start or change your medicine to control your blood sugar levels. Report to your doctor right away if you get new or worsening signs and symptoms of high blood sugar such as feeling thirsty, confused, and tired. This tablet might cause breathing difficulty and problems with thinking. Hence it is advisable to avoid driving or operating machines during this treatment. Before starting this treatment, inform your doctor if you are taking any prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.
FAQs
Q 1. Can I drink alcohol while taking Lorbriqua 25mg tablet?
It is generally recommended to avoid drinking alcohol while taking Lorbriqua 25mg tablet, as alcohol can increase the risk of liver damage.
Q 2. What should you know before taking Lorbriqua 25mg tablets?
Lorbriqua 25mg tablets can alter cholesterol and triglyceride levels in the blood, slow down heart rate, increase your blood pressure and glucose levels. Hence, your health care provider will monitor your symptoms and blood parameters before and during this treatment.
Q 3. Is it safe for women of reproductive age to use Lorbriqua 25mg Tablet?
While for women with reproductive potential subjected to Lorbriqua 25mg Tablet, it is advisable to discuss with your doctor the effective birth control methods (non-hormonal) during the treatment. Also, it is essential to continue birth control treatment for a minimum of 6 months after the last dose, as this medicine may impair fertility.
Q 4. What should you do if you miss a dose of Lorbriqua 25mg Tablet?
If you miss a dose of Lorbriqua 25mg Tablet, take it as soon as you remember. However, if your next dose is due within 4 hours, skip this dose and take your next dose at your regular time. Do not take 2 doses to make up for your missed dose.
Q 5. What are the side effects of Lorbriqua 25mg Tablet?
The common side effects that are likely to occur while you are on the treatment with Lorbriqua 25mg tablet are Swelling of arms, legs, hands, and feet, numbness and tingling, weight gain, forgetfulness, confusion, tiredness, breathing difficulty, joint pain, diarrhea, depression, irritability, high cholesterol and triglyceride levels, and cough.
Q 6. When should you contact your physician?
Reach out to your physician right away if you experience problems with thinking like forgetfulness or confusion, seeing or hearing things that are not real, depression, suicidal thoughts, seizures, changes in speech or sleep pattern.
Fact Box of Lorbriqua 25mg Tablet
Molecule name: Lorlatinib | Therapeutic class: Anti neoplastics |
Pharmacological class: Tyrosine kinase inhibitor | Indications: 1.Metastatic non-small cell lung cancer (NSCLC) |
References
- Pfizer Ltd, [Revised on Mar 2021] [Accessed on 1st April 2023], https://labeling.pfizer.com/ShowLabeling.aspx?id=11140&Section=PPI
- Pfizer Ltd, Electronic medicines compendium (emc), [Revised on March 2021] [Accessed on 1st April 2023], https://www.medicines.org.uk/emc/files/pil.10632.pdf
- Pfizer, US Food and Drug Administration, [Revised on March 2021] [Accessed on 1st April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
- Alice T Shaw et al; First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer; The New England Journal of Medicine; Published on 19/11/2020;[Accessed on 1st April 2023]; https://pubmed.ncbi.nlm.nih.gov/33207094/
- Haidar El Darsa, Omar Abdel-Rahman & Randeep Sangha (2020) Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer, Expert Opinion on Pharmacotherapy, 21:13, 1547-1554,[Accessed on 1st April 2023], https://doi.org/10.1080/14656566.2020.1774552
- Gafer H, de Waard Q, Compter A, van den Heuvel M. Rapid regression of neurological symptoms in patients with metastasis ALK+ lung cancer who are treated with lorlatinib: a report of two cases. BMJ Case Rep. 2019 Jul 24;12(7):e227299,[Accessed on 1st April 2023], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663151/pdf/bcr-2018-227299.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
